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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYPreviously, we described the safety and therapeutic potential of neurospheres (NSs) derived from a human induced pluripotent stem cell
(iPSC) clone, 201B7, in a spinal cord injury (SCI) mousemodel. However, several safety issues concerning iPSC-based cell therapy remain
unresolved. Here, we investigated another iPSC clone, 253G1, that we established by transducing OCT4, SOX2, and KLF4 into adult hu-
man dermal fibroblasts collected from the same donor who provided the 201B7 clone. The grafted 253G1-NSs survived, differentiated
into three neural lineages, and promoted functional recovery accompanied by stimulated synapse formation 47 days after transplanta-
tion. However, long-term observation (for up to 103 days) revealed deteriorated motor function accompanied by tumor formation. The
tumors consisted of Nestin+ undifferentiated neural cells and exhibited activation of the OCT4 transgene. Transcriptome analysis re-
vealed that a heightened mesenchymal transition may have contributed to the progression of tumors derived from grafted cells.INTRODUCTION
Advances in stem-cell-based therapies may help overcome
CNS disorders such as spinal cord injury (SCI). Transplanta-
tion of neural stem/progenitor cells (NS/PCs) has yielded
beneficial effects and improved functional recovery in
SCI animal models (Cummings et al., 2005; Hofstetter
et al., 2005; Iwanami et al., 2005; Ogawa et al., 2002; Okada
et al., 2005; Salazar et al., 2010; Yasuda et al., 2011). Plurip-
otent stem cells (PSCs), including embryonic stem cells
(ESCs) and induced PSCs (iPSCs), can differentiate into
NS/PCs (Falk et al., 2012; Fujimoto et al., 2012a; Kumagai
et al., 2009; Miura et al., 2009; Nori et al., 2011; Okada
et al., 2004, 2008; Tsuji et al., 2010), oligodendrocyte pre-
cursor cells (OPCs) (Keirstead et al., 2005; Wang et al.,
2013), and motoneuron progenitors (Erceg et al., 2010; Lu-
kovic et al., 2014) in vitro. Previous studies demonstrated
the therapeutic potential of mouse and human iPSC-
derived NS/PCs for SCI in mice and non-human primates
(Fujimoto et al., 2012b; Kobayashi et al., 2012; Nori et al.,
2011; Tsuji et al., 2010). However, tumorigenicity remains
a major concern for clinical applications of iPSCs.
Previously, we reported the safety and therapeutic po-
tential of human iPSC-derived neurospheres (iPSC-NSs)360 Stem Cell Reports j Vol. 4 j 360–373 j March 10, 2015 j ª2015 The Authfor SCI in non-obese diabetic–severe combined immuno-
deficient (NOD-SCID) mice (Nori et al., 2011) using the
iPSC clone 201B7 (Nori et al., 2011; Takahashi et al.,
2007). Here, we aimed to characterize novel NS/PCs
derived from a different iPSC clone, 253G1. We estab-
lished this clone from the same adult human dermal fibro-
blasts used for 201B7 by transducing three reprogram-
ming factors: OCT4, SOX2, and KLF4 (Nakagawa et al.,
2008). Grafted 253G1-derived neurospheres (253G1-NSs)
survived and differentiated into three neural lineages in
the injured spinal cord, and some of the resultant cells
formed synapses with host neurons. Motor function in
grafted mice initially recovered but then gradually
declined, and tumors emerged during long-term observa-
tion. These tumors consisted of undifferentiated Nestin+
cells, but not NANOG+ pluripotent cells. Late-onset acti-
vation of the OCT4 transgene (Tg) may be associated
with tumor formation. Transcriptome analysis revealed
altered expression of genes involved in the epithelial-
mesenchymal transition (EMT), which is related to
tumor invasion and progression. Moreover, canonical
pathway analysis revealed upregulation of the Wnt/b-cat-
enin signaling pathway after 253G1-NS transplantation,
which played a critical role in tumor development.ors
Thus, although 253G1-NSs conferred temporary func-
tional recovery in mice with SCI, they later developed
into tumors and worsened the overall outcome.RESULTS
Grafted 253G1-NSs Survive in Injured Spinal Cord and
Differentiate into Three Neural Lineages
Immunodeficient (NOD-SCID) mice were used for xeno-
graft experiments. After laminectomy, contusive SCI was
induced at the Th10 level. Nine days after injury, 5 3 105
253G1-NS-derived cells, whichwere lentivirally transduced
with the fluorescent protein Venus (an altered yellow fluo-
rescent protein; Nagai et al., 2002) or ffLuc (Venus fused to
firefly luciferase; Hara-Miyauchi et al., 2012), were injected
into the lesion epicenter. Histological analyses were per-
formed 47 days (d) after transplantation. The grafted
253G1-NSs survived, migrated into the host spinal cord
(Figures 1A and 1B), and differentiated into neuronal
nuclei (NeuN)+ (17.2% ± 2.6%) and b-tubulin isotype III
(bIII tubulin)+ (42.2% ± 3.1%) neurons, glial fibrillary acidic
protein (GFAP)+ astrocytes (15.0% ± 0.7%), and adenoma-
tous polyposis coli CC-1 (APC)+ oligodendrocytes (2.7% ±
0.3%; Figures 1C–1G). Quantitative analysis revealed that
67% of NeuN+ mature neurons were GAD67+ GABAergic
neurons (Figure 1H). Small numbers of grafted cells
differentiated into tyrosine hydroxylase (TH)+ and choline
acetyltransferase (ChAT)+ cholinergic neurons (Figures 1I
and 1J).Grafted 253G1-NS-Derived Neurons Form Synaptic
Connections with Host Neurons
We performed triple immunostaining for human nu-
clear protein (HNu) and two neuronal markers, bIII
tubulin and the presynaptic protein Bassoon (Bsn).
Because the anti-Bsn antibody selectively recognized
the mouse and rat epitopes, but not the human epitopes
(Figure S1), we were able to evaluate the ability of
253G1-NS-derived neurons to integrate with the host
neural circuitry using this approach. Grafted bIII
tubulin+/HNu+ cells in parenchymal locations were
contacted by synaptic boutons of host neurons (Fig-
ure 1K). Moreover, triple immunostaining for HNu,
bIII tubulin, and human-specific synaptophysin (hSyn)
revealed dense terminal fields of human-derived bou-
tons apposed to host neurons (Figure 1L). Host ChAT+
neurons in the ventral gray matter were contacted by
the hSyn+ graft-specific terminals (Figure 1M). Im-
muno-electron microscopy also revealed Venus+ human
pre- and post-synaptic structures, as well as synapse for-
mation between host neurons and Venus+ 253G1-NS-
derived neurons (Figure 1N).Stem CGrafted 253G1-NSs Promote Motor Function Recovery
after SCI
We assessed motor function recovery using the Basso
mouse scale (BMS) score, Rotarod test, andDigiGait system.
According to the BMS score, the 253G1-NS-grafted group
exhibited significantly better functional recovery than
the PBS-injected control groupR12 days after transplanta-
tion (BMS score = 3.2 ± 0.1 at 12 days post-transplantation
and 3.3 ± 0.2 at 47 days post-transplantation; Nori et al.,
2011; Figure 1O). In the Rotarod test, 253G1-NS-grafted
mice remained on the rod significantly longer (61.1 ± 7.1
s) than the control group (33.0 ± 7.3 s; Nori et al., 2011)
at 47 days post-transplantation (Figure 1P). Gait perfor-
mance was evaluated using the DigiGait image analysis
system. All 253G1-NS-grafted mice could walk on the
treadmill at 8 cm/s, whereas some control mice (4/16)
could not. Stride length was significantly longer in the
253G1-NS-grafted group (4.2 ± 0.1 cm) than in the control
group (2.2 ± 0.1 cm; Nori et al., 2011; Figure 1Q).
Tumors Form after 253G1-NS Transplantation,
Resulting in Deteriorated Motor Function
We extended the follow-up period to 103 days post-trans-
plantation to investigate the long-term safety of the grafted
253G1-NSs. Although recovery ofmotor function persisted
for up to 47 days post-transplantation, 253G1-NS-grafted
mice exhibited gradual deterioration of hind limb motor
function thereafter (Figure 2A). To monitor the survival
and growth of the grafted cells in the mouse spinal cord,
we lentivirally transduced 253G1-NSs with ffLuc, which
allowed us to identify grafted cells by their bioluminescent
luciferase signals and fluorescent Venus signals. The
photon count of grafted 253G1-NSs decreased within the
first week post-transplantation, but gradually increased at
14 days post-transplantation and thereafter, demon-
strating the survival and growth of the grafted cells. Be-
tween 42 and 70 days post-transplantation, the photon
counts sharply increased (Figures 2B and 2C), consistent
with the deterioration of the BMS score shown in Figure 2A.
At 103 days post-transplantation, the photon count of the
grafted 253G1-NSs increased more than 10-fold from its
initial value (Figure 2C).
Histological analyses revealed tumors in 253G1-NS-
grafted spinal cords. These tumors were divided into three
groups based on the diameter of the lesion (small-tumor
group, f < 200 mm; medium-tumor group, 200 < f <
700 mm; large-tumor group, 700 mm < f). Some of the tu-
mors (12/22) exhibited microcystic masses consisting of
HNu/Nestin double-positive human-derived bipolar cells
with hair-like processes. These masses were observed in
all tumors from the large-tumor group (7/7; Figures 2D
and 2E show representative images of microcystic masses
from the large-tumor group). Suchmasses were also presentell Reports j Vol. 4 j 360–373 j March 10, 2015 j ª2015 The Authors 361
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Figure 1. Grafted 253G1-NSs Mainly Differentiate into Neurons and Form Synapses with Host Spinal Cord Neurons
(A and B) Venus+ 253G1-NSs integrated into the mouse spinal cord. Arrowheads indicate the lesion epicenter.
(C–F) Representative images of Venus+ grafted cells immunostained for the markers NeuN (mature neurons) (C), bIII tubulin (all neurons)
(D), GFAP (astrocytes) (E), and APC (oligodendrocytes) (F).
(G) Percentages of cell-type-specific marker-positive cells among Venus+ grafted cells at 47 days post-transplantation. Values are
expressed as the mean ± SEM (n = 4 mice).
(H) Most 253G1-derived neurons differentiated into GAD67+ (GABAergic) neurons.
(I and J) TH+/HNu+ neurons and ChAT+/HNu+ neurons were observed, but were rare.
(K) Sections were triple stained for HNu (green), bIII tubulin (red), and the presynaptic marker Bassoon (Bsn, white). The Bsn antibody
recognized the mouse, but not the human, protein.
(L) Sections triple stained for HNu (green), bIII tubulin (red), and the human-specific presynaptic marker hSyn (white). bIII tubulin+/
HNu neurons represented host mouse neurons. The hSyn antibody recognized the human, but not the mouse, protein.
(M) Large numbers of somatic and dendritic terminals from graft-derived nerve cells were present on host ChAT+ motor neurons at the
ventral horns.
(N) Electron microscopy (EM) images show synapse formation between host mouse neurons and graft-derived Venus+ (black) human
neurons. Pre- and post-synaptic structures indicate transmission from a graft-derived neuron to a host neuron, and from a host neuron to a
graft-derived neuron. H, host neuron; G, graft-derived neuron; arrowheads, post-synaptic density.
(O) Motor function in the hind limbs was assessed weekly using the BMS score until 47 days post-transplantation. Values are expressed as
the mean ± SEM (n = 32 mice).
(P) Rotarod test 47 days after transplantation. Graph shows total run time. Values are expressed as the means ± SEM (n = 10 mice).
(Q) Treadmill gait analysis using the DigiGait system 47 days post-transplantation. Graph shows stride length. Values are expressed as the
means ± SEM (n = 19 mice). Behavioral analyses were performed by two observers who were blinded to the treatment conditions.
Scale bars, 1,000 mm in (A); 100 mm in (B); 50 mm in (J-1); 20 mm in (F-3), (F-4), (H-1), (J-2), (K-1), (L-1), and (M-1); 10 mm in (H-2),
(J-3), (K-2), (L-2), and (M-2); 0.5 mm in (N). See also Figure S1.
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Figure 2. Tumor Formation during Long-Term Observation after 253G1-NS Transplantation
(A) Up to 103 days post-transplantation, motor function in the hind limbs was assessed weekly using the BMS score. Values are expressed
as the means ± SEM (n = 32 mice up to 47 days post-transplantation; thereafter, n = 22 mice until 103 days post-transplantation).
(B) Representative in vivo images of mice at 0, 14, 42, 70, and 103 days after 253G1-NS transplantation.
(C) Quantitative analysis of photon counts derived from grafted cells. Values are expressed as the means ± SEM (n = 20 mice up to 42 days
post-transplantation; thereafter, n = 14 mice until 103 days post-transplantation).
(D) Representative hematoxylin and eosin (H&E) image of a large tumor (700 mm < f).
(E) Boxed area in (D).
(E1–E3) Immunohistochemistry showing that most grafted cells in the microcystic area were Nestin+.
(F) Representative H&E image of a medium tumor (200 < f < 700 mm).
(G) Boxed area in (F). Immunohistochemistry shows that some grafted cells exhibited normal neural differentiation.
(H and I) Boxed area in (F). Some grafted cells formed microcystic masses that were positive for Nestin.
(J) Percentages of cell-type-specific, marker-positive cells among HNu+ grafted cells at 103 days post-transplantation. Values represent
the means ± SEM (n = 4 and 10 mice for 47 and 103 days post-transplantation, respectively). *p < 0.05, **p < 0.01.
Scale bars, 500 mm in (D) and (F), 50 mm in (E) and (G–I). See also Figure S2.
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Figure 3. Histological and Gene-Expression Analyses of Tumors
(A) Schematic of histological analyses of tumors.
(B) Correlation between tumor diameter and the proportion of grafted cells that were Nestin+ at 47 and 103 days post-transplantation (TP).
(C) Correlation between tumor diameter and the proportion of grafted cells that were Ki-67+.
(D) Correlation between tumor diameter and the proportion of grafted cells that were OCT4+.
(E) Correlation between the tumor diameter and the proportion of grafted cells that were OCT4+/HNu+ at 103 days after TP.
(F) Correlation between the number of days after TP (47 or 103 days after TP) and the proportion of grafted cells that were OCT4+. In
(B)–(F), n indicates the number of mice.
(G) Schematic of mRNA expression analyses of tumors.
(H–M) The expression of human OCT4-Tg, OCT4-Endo, SOX2-Tg, SOX2-Endo, KLF4-Tg, KLF4-Endo, c-MYC-Tg, and c-MYC-Endo mRNA in 253G1
cells, 253G1-NSs, 103-day post-transplant 253G1-NSs (TP 103d), and adult human dermal fibroblasts (HDFs) was analyzed by RT-PCR. Data
(legend continued on next page)
364 Stem Cell Reports j Vol. 4 j 360–373 j March 10, 2015 j ª2015 The Authors
in the majority of the medium tumors (5/7), whereas none
were found in the small-tumor group (0/8). In medium tu-
mors that exhibited microcystic masses, some grafted cells
underwent normal neural differentiation (Figures 2F and
2G). However, a portion of the grafted cells formed micro-
cystic masses positive for Nestin (Figures 2H and 2I), and
Nestin+ cells were also observed outside the microcystic
mass. Significantly higher percentages of Nestin+ cells
(34.2% ± 7.3%) and APC+ oligodendrocytes (5.4% ±
0.7%), as well as significantly lower percentages of bIII
tubulin+ neurons (32.1% ± 5.1%), were observed at
103 days relative to 47 days (Figure 2J). In addition,
15.8% ± 2.7% of grafted cells had differentiated into astro-
cytes at 103 days. Taken together, these data indicate that
approximately 87.5% of grafted cells differentiated toward
neural lineages.We observed no NANOG+ pluripotent cells
in grafted 253G1-NSs at 103 days post-transplantation
(Figure S2).
Next, we examined the correlation between tumor diam-
eter and the percentages of Nestin+, Ki-67+, or OCT4+ cells
among HNu+ grafted cells (Figure 3A). Statistical analysis
revealed a significant correlation between tumor diameter
and the percentage of Nestin+/HNu+ cells (Figure 3B).
Compared with the small-tumor group, the large- and
medium-tumor groups contained significantly higher
percentages of Ki-67+/HNu+ cells and OCT4+/HNu+ cells
(Figures 3C and 3D). However, there was no significant cor-
relation between tumor diameter and the percentage of
OCT4+/HNu+ cells at 103 days post-transplantation (Fig-
ure 3E). Meanwhile, significantly more OCT4+/HNu+ cells
were observed at 103 days than at 47 days (Figure 3F);
thus, the percentage of OCT4+/HNu+ cells correlated posi-
tively with post-transplant duration.
We also evaluated the expression of human OCT4-Tg,
OCT4-endogenous (Endo), SOX2-Tg, SOX2-Endo, KLF4-
Tg, and KLF4-Endo mRNAs in 253G1 cells, 253G1-NSs,
and spinal cord tissues of the 253G1-NS-grafted group,
which were harvested at 103 days post-transplantation
(253G1-NS/transplantation [TP]-103d group; Figures 3G–
3M). Compared with 253G1-NSs, OCT4-Tg expression
was significantly higher in 253G1-NS/TP-103d spinal cords
(Figure 3H), whereas OCT4-Endo expression was only
observed in the 253G1 iPSCs (Figure 3I). SOX2-Endo was
expressed in both 253G1-NSs and the 253G1-NS/TP-103d
group, and levels of SOX2-Endo slightly increased after
transplantation (Figure 3K). KLF4-Tg expression was also
elevated in 253G1-NSs and the 253G1-NS/TP-103d group
(Figure 3L).are presented as expression levels relative to the control (HDFs) 11 day
represent the means ± SEM (n = 3 independent experiments).
The p values shown in (B)–(F) were calculated using Scheffe’s test,
Kruskal-Wallis non-parametric test: (B) 5.00E-06, (C) 7.20E-06, (D) 0
Stem CTranscriptomic Differences between 253G1-NSs and
201B7-NSs Post-Transplantation
Comparative transcriptome analyses of grafted cells and
surrounding host cells can reveal information regarding
the differentiation status of the grafted cells and the effects
of the graft on the host tissue. mRNA sequencing (mRNA-
seq) enables one to analyze the global expressionof individ-
ual human andmouse genes from amixture of human and
mouse cells (Bradford et al., 2013). Here, we sought to mea-
sure expression in mouse spinal cord tissue containing hu-
man cells derived fromgraftedhuman iPSC-NSs. To analyze
mRNA expression in both grafted human iPSC-NSs and
host spinal cord tissue, we analyzed the mRNA from NSs
of 253G1 and 201B7 cells, as well as mouse spinal cord tis-
sues containing grafted 253G1-NSs and 201B7-NSs, which
were harvested at 5 and 103 days post-transplantation
(PBS-5d and 103d, 253G1-NS/TP-5d and 103d, and
201B7-NS/TP-5d and 103d). The ratio of human andmouse
mRNA-seq reads derived from epicenter segments (8mm in
length) of iPSC-NS-grafted spinal cord tissuewas considered
to reflect the ratio of human andmouse cells (Table S1). The
global gene-expression patterns of these tissueswere hierar-
chically clustered into5-day (PBS-5d, 253G1-NS/TP-5d, and
201B7-NS/TP-5d) and 103-day groups (PBS-103d, 253G1-
NS/TP-103d, and 201B7-NS/TP-103d), which may reflect
time-dependent changes in the spinal cord microenviron-
ment following SCI (Figure 4A). Similarly, the gene-expres-
sionprofiles of the grafted iPSC-NSs clustered on thebasis of
time post-transplantation (NS, 5 and 103 days) rather than
clonal (253G1 and 201B7) origin (Figure 4B). However, the
profiles of the two clones diverged at 103 days post-trans-
plantation. Furthermore, the gene-expression profiles of
253G1-NS/TP-103d and 201B7-NS/TP-103d differed signif-
icantly (Figures 4C and 4D).
Next, we identified human genes that were upregulated
in the mouse spinal cord at 103 days post-transplantation
relative to iPSC-NSs before transplantation (fold change >
5.0). As shown in the Venn diagram in Figure 4E, we iden-
tified 692 genes in the 253G1-NS/TP-103d group, 335
genes in the 201B7-NS/TP-103d group, and 1,023 genes
in both the 253G1-NS/TP-103d and 201B7-NS/TP-103d
groups that were expressed at higher levels than in
253G1-NSs and 201B7-NSs. Gene Ontology (GO) analysis
of the 335- and 1,023-gene groups indicated that synapto-
genesis was occurring in both the 253G1- and 201B7-NS/
TP-103d groups (Tables 1 and S2). GO analysis of the 692
genes that were exclusively activated in 253G1-derived
cells at 103 days post-transplantation identified as after retroviral transduction of OCT4, SOX2, KLF4, and c-MYC. Values
and p values to determine significance were calculated using the
.01, and (F) 1.33E-04. *p < 0.05, **p < 0.01. ns, non-significant.
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Figure 4. Global Human Gene-Expression Analysis
(A) Hierarchical clustering analysis of mouse gene-expression data from spinal cord tissues of the PBS-5d and -103d, 253G1-NS/TP-5d and
-103d, and 201B7-NS/TP-5d and -103d groups.
(B) Hierarchical clustering analysis of human gene-expression data: 253G1-NSs and 201B7-NSs, as well as spinal cord tissues of the 253G1-
NS/TP-5d and -103d, and 201B7-NS/TP-5d and -103d groups. In (A) and (B), the signal intensity of each gene is displayed as a heatmap
colored according to the expression level.
(legend continued on next page)
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Table 1. Gene Ontology Analysis of 335 Human Genes
Upregulated in 201B7-NS-Grafted Spinal Cord
GO Accession GO Term Corrected p Value
GO:0045202 synapse 7.05E-08
GO:0007399 nervous system development 3.56E-06
GO:0007267 cell-cell signaling 7.69E-06
GO:0019226 transmission of nerve impulse 4.68E-04
GO:0043005 neuron projection 1.76E-03
GO:0030182 neuron differentiation 1.26E-02
GO:0007154 cell communication 1.26E-02
GO:0048699 generation of neurons 1.40E-02
GO:0022008 neurogenesis 1.91E-02
GO:0050806 positive regulation of
synaptic transmission
3.52E-02
GO:0050804 regulation of synaptic
transmission
4.19E-02
GO:0007417 central nervous system
development
4.80E-02
GO:0051971 positive regulation of
transmission of nerve impulse
4.80E-02
See also Table S2.number of mesenchyme-associated terms, including
‘‘mesenchymal cell differentiation,’’ ‘‘mesenchymal cell
development,’’ and ‘‘epithelial tomesenchymal transition’’
(Table 2). These terms were also identified in a comparison
of 253G1 and 201B7 NS cells, suggesting that 253G1-NS
cells were more prone to undergo EMT (Table S3). Further-
more, the mRNA-seq data revealed that EMT-related genes
such as LEF1, BMP2, HGF, SNAI1, SNAI2, TWIST1, and
TWIST2 (as suggested by GO analysis and previous reports(C) Principal-component analysis (PCA) of human gene-expression da
z axis, component 3 (13.88%).
(D) Two-dimensional PCA of human gene expression data. x axis, com
(E) Venn diagram of human genes whose expression increased in the 2
NSs and 201B7-NSs. Color key: red, 692 genes highly expressed in the
201B7-NS/TP-103d group; purple, 1,023 genes highly expressed in b
(F–L) EMT-related human gene expression in 253G1- and 201B7-NSs a
means ± SEM (n = 1 each in the human iPSC-NS, n = 2 for 201B7-NS/TP
independent experiments).
(M–P) The expression of SNAI1, SNAI2, TWIST1, and TWIST2 mRNA in
sented as expression levels relative to the control (the U87 human
independent experiments).
(Q) Representative H&E image of the mid-sagittal section 103 days a
(R) p-STAT3-stained image of the adjacent section of (Q). Arrow, les
(S) Boxed area in (R).
Scale bar, 1,000 mm in (Q) and (R), 100 mm in (S). *p < 0.05, **p <
Stem C[Moody et al., 2005; Yang et al., 2004]) were significantly
upregulated in the 253G1-NS/TP-103d group relative to
the 201B7-NS/TP-103d group (Figures 4F–4L).We also eval-
uated the expression of SNAI1, SNAI2, TWIST1, and
TWIST2 mRNAs in 201B7-NSs and 253G1-NSs prior to
transplantation (Figures 4M–4P). Expression of SNAI2,
TWIST1, and TWIST2 was significantly higher in 253G1-
NSs than in 201B7-NSs (Figures 4N–4P), whereas SNAI1
expression was significantly lower in 253G1-NSs than in
201B7-NSs (Figure 4M). Furthermore, we evaluated the
signal transducer and activator of transcription 3 (STAT3),
extracellular-signal-regulated kinase (ERK) and v-akt mu-
rine thymoma viral oncogene (AKT) pathways, which are
involved in tumormaintenance. Specifically, we performed
immunohistochemical analyses to monitor the levels of
tyrosine 705-phosphorylated STAT3 (p-STAT3), tyrosine
202/204-phosphorylated ERK1/2 (p-ERK1/2), and serine
473-phosphorylated AKT (p-AKT). We observed p-STAT3+
cells (Figures 4Q–4S), but no p-ERK1/2+ or p-AKT+ cells,
in the 253G1-NS/TP-103d group.Ingenuity Pathway Analysis Revealed Pathways that
Differed Significantly between 253G1-NS and 201B7-
NS Transplantation
We used Ingenuity Pathway Analysis (IPA) to identify path-
ways differentially expressed between the 253G1-NS/TP-
103d and 201B7-NS/TP-103d groups. IPA detected a total
of 56 significantly altered (p < 0.05) pathways. Figure 5
shows the ten most altered pathways, all of which were
significantly upregulated in the 253G1-NS/TP-103d group
relative to iPSC-NSs prior to transplantation.DISCUSSION
Because we generated the human iPSC clone 253G1
without introducing c-MYC, we initially speculated thatta. x axis, component 1 (41.03%); y axis, component 2 (24.21%);
ponent 1 (41.03%); y axis, component 2 (24.21%).
53G1-NS/TP-103d and 201B7-NS/TP-103d groups relative to 253G1-
253G1-NS/TP-103d group; blue, 335 genes highly expressed in the
oth the 253G1- and 201B7-NS/TP-103d groups.
nd the 253G1- and 201B7-NS/TP-103d groups. Values represent the
-103d, and n = 3 for 253G1-NS/TP-103d; n indicates the number of
201B7-NSs and 253G1-NSs was analyzed by RT-PCR. Data are pre-
glioblastoma cell line). Values represent the means ± SEM (n = 3
fter transplantation.
ion epicenter; arrowhead, distribution of grafted 253G1-NSs.
0.01. See also the mRNA-seq read distribution in Table S1.
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Table 2. Gene Ontology Analysis of 692 Human Genes
Upregulated in 253G1-NS-Grafted Spinal Cord
GO Accession GO Term Corrected p Value
GO:0030198 extracellular matrix
organization and biogenesis
2.29E-16
GO:0001501 skeletal development 1.29E-14
GO:0043062 extracellular structure
organization and biogenesis
2.67E-13
GO:0001568 blood vessel development 1.88E-12
GO:0001944 vasculature development 3.51E-12
GO:0030199 collagen fibril organization 5.50E-08
GO:0014031 mesenchymal cell
development
2.78E-07
GO:0048762 mesenchymal cell
differentiation
4.84E-07
GO:0001525 Angiogenesis 2.81E-06
GO:0048514 blood vessel morphogenesis 3.02E-06
GO:0001503 ossification 1.74E-05
GO:0031214 biomineral formation 1.89E-05
GO:0014032 neural crest cell development 5.94E-04
GO:0014033 neural crest cell
differentiation
7.55E-04
GO:0007517 muscle development 3.04E-03
GO:0042127 regulation of cell proliferation 4.84E-03
GO:0001837 epithelial to mesenchymal
transition
2.02E-02
See also Table S3.253G1-NSs would be less tumorigenic than 201B7-NSs.
Therefore, we performed transplantation of 253G1-NSs to
treat SCI in adult NOD-SCID mice. Like the 201B7-NSs,
the grafted 253G1-NSs differentiated into three neural lin-
eages, reconstructed local circuitry, and promoted angio-
genesis as well as axonal regrowth (data not shown).
Thus, 253G1-NS transplantation promotedmotor function
recovery after SCI in NOD-SCID mice.
When considering the clinical use of iPSC-NSs, it is
important to address safety issues, especially with regard
to tumorigenicity. To this end, we extended the observa-
tion period after transplantation. Previously, we reported
that 201B7-NS-grafted mice maintained functional recov-
ery until 103 days post-transplantation, and confirmed
that 201B7-NSs were non-tumorigenic based on histologi-
cal findings (Nori et al., 2011). Here, we found that
253G1-NS-grafted mice exhibited temporary motor func-368 Stem Cell Reports j Vol. 4 j 360–373 j March 10, 2015 j ª2015 The Authtion recovery for up to 47 days post-transplantation; how-
ever, this was followed by a gradual deterioration in motor
function, along with grafted cell proliferation and tumor
development. Bioluminescence imaging revealed that the
photon count of the grafted cells increased more than 10-
fold from the initial value by 103 days after transplanta-
tion. These tumors were negative for the pluripotency
marker NANOG. Tumor size correlated with the proportion
of Nestin+ cells in the graft at 103 days post-transplanta-
tion. Previously, we showed that after 201B7-NS transplan-
tation, the proportion of grafted cells that were Nestin+
decreased from 10.7% ± 2.2% at 47 days to 7.5% ± 1.0%
at 103 days post-transplantation, resulting in no evidence
of tumorigenicity (Nori et al., 2011). By contrast, the pro-
portion of Nestin+ cells increased from 19.6% ± 0.5% at
47 days to 33.1% ± 7.4% at 103 days after 253G1-NS
transplantation, suggesting that differentiation-resistant
Nestin+ cells proliferated over time and formed tumors.
Consistent with this, the proportion of Ki-67+ cells signifi-
cantly increased from 1.7% ± 0.17% at 47 days to 3.0% ±
0.2% at 103 days after 253G1-NS transplantation, which
is significantly higher than what was observed after
201B7-NS transplantation. These findings suggest that
the proportion of proliferating cells increased over time
and induced tumor formation in 253G1-NS-grafted mice
in the long term.
Tumor diameter exhibited no significant correlationwith
the proportion of OCT4+/HNu+ cells. Instead, the propor-
tion of grafted cells that were OCT4+ was solely dependent
on the post-transplantation observation period. In our pre-
vious study, we observed no evidence of OCT4+/HNu+ cells
or tumor formation in 201B7-NS-grafted mice after long-
term observation (Nori et al., 2011). It is likely that the
chronologically increasing OCT4 expression in the grafted
253G1-NSs is related to tumor formation, consistent with
the results of RT-PCR, which showed that the expression
of OCT4-Tg at 103 days post-transplantation was signifi-
cantly higher than that in untransplanted 253G1-NSs.
OCT4 is a key regulator of self-renewal and plays a critical
role in maintaining ESC pluripotency (Niwa, 2007). In
addition, OCT4 is sometimes re-expressed in somatic cells
during carcinogenesis (Monk and Holding, 2001). OCT4
is also highly expressed in human gliomas and glioma
cell lines, and OCT4 overexpression in glioma cells induces
Nestin expression by inhibiting glioma cell differentiation
(Du et al., 2009; Ikushima et al., 2011). These findings are
consistent with the results we describe here, even though
the tumors observed in the present study were not patho-
logically identical to gliomas. We also observed that
KLF4-Tg was activated in 253G1-NSs, and that its expres-
sion increased after transplantation. KLF4 is highly ex-
pressed in primary breast ductal carcinoma and oral
squamous carcinoma (Foster et al., 2005; Pandya et al.,ors
Figure 5. The Most Significantly Altered
Common Pathways after Transplantation
of 253G1- and 201B7-NSs, as Revealed
by Ingenuity Pathway Analysis
Canonical pathway analysis identified the
pathways from the Ingenuity Pathway
Analysis library that were significantly en-
riched in the data set. Only genes that
showed a fold change R 3.0 were consid-
ered in this analysis. The black bars show
the human gene set in the 253G1-NS/TP-
103d group versus the 201B7-NS/TP-103d
group. The white bars show the comparison
of the human gene set in 253G1-NSs versus
201B7-NSs in the same pathway. Bars
represent the logarithmic values (log10) of
the significance level (p); the solid line
corresponds to the threshold of p = 0.05.2004). Previous reports also showed that KLF4 overexpres-
sion promotes self-renewal in ESCs (Li et al., 2005), and
KLF4 is an essential reprogramming factor that functions
by binding at Oct4 loci to initiate Oct4 transcription and
complete the reprogramming process (Wei et al., 2013).
These results suggest that KLF4 plays an important role
in maintaining PSCs, and that the tumor formation we
observed could be related to KLF4-Tg activation.
In a previous study, themolecular properties of engrafted
NS/PCs changed dramatically depending on the spinal
cord microenvironment (Kumamaru et al., 2012). Here,
we analyzed the changes in the microenvironment of
mouse spinal cord tissues affected by iPSC-NS transplanta-
tion. We observed no significant differences in the mouse
gene-expression profiles of spinal cord tissues among the
253G1-NS/TP, 201B7-NS/TP, and control groups, suggest-
ing that mouse gene expression did not widely affect
tumorigenesis in grafted iPSC-NSs. However, human
gene-expression profiles from the 253G1- and 201B7-NS/
TP groups differed in a time-dependent manner, whichStem Cmay have been related to tumor formation in the 253G1-
NS/TP group. GO analysis revealed increased progression
of EMT in the 253G1-NS and 253G1-NS/TP groups relative
to the 201B7-NS and 201B7-NS/TP groups.
During EMT, epithelial cells lose their epithelial char-
acteristics and acquire the properties of migratory
mesenchymal cells. This process is associated with the
early stages of carcinogenesis, cancer invasion, and
recurrence (Hay, 1995; Thiery, 2002). Brain tumors,
including some human gliomas, also contain stem-like
cells with both neural and mesenchymal potential that
are implicated in both tumor progression and invasive-
ness (Ricci-Vitiani et al., 2008). STAT3 is frequently over-
expressed in cancers, including gliomas (Abou-Ghazal
et al., 2008), and STAT3 phosphorylation leads to the
transcriptional activation of genes involved in processes
such as cell proliferation, apoptosis suppression, and
angiogenesis (Bowman et al., 2001). Moreover, STAT3
regulates the EMT gene TWIST (Cheng et al., 2008),
consistent with the more active EMT progression andell Reports j Vol. 4 j 360–373 j March 10, 2015 j ª2015 The Authors 369
elevated TWIST expression in the 253G1-NS/TP group
observed in this study. Mesenchyme-like changes in
253G1-NSs following transplantation may contribute to
the biological characteristics of tumor cells derived
from parental 253G1-NSs.
IPA revealed upregulation of human ESC pluripotency
pathways in post-transplantation 253G1-NSs. This phe-
nomenon might be related to the population of differenti-
ation-resistant Nestin+ cells that proliferated over time and
formed tumors. Furthermore, the Wnt/b-catenin signaling
pathway was significantly upregulated in the 253G1-NS/
TP group. Previous studies showed that Wnt/b-catenin
signaling is critical for regulating the self-renewal, prolifer-
ation, and differentiation of NS/PCs in the brain (Gong and
Huang, 2012), and that this pathway leads to enhanced
TERT expression in human cancers, resulting in the stabili-
zation of telomeres, a hallmark of tumorigenesis (Hoff-
meyer et al., 2012). In part, the tumorigenicity of 253G1-
NSs could be related to upregulation of the Wnt/b-catenin
signaling pathway. Moreover, consistent with GO analysis,
regulation of the EMT pathway was significantly upregu-
lated in the 253G1-NS/TP group relative to the 207B7-NS/
TP group.
Recently, several clinical trials of stem-cell-based therapy
for SCI using either human NS/PCs (Cummings et al.,
2005; Salazar et al., 2010) or human ESC-derived OPCs
(Strauss, 2010) have been initiated. Compared with these
stem cells, iPSCs raise fewer ethical concerns in certain
countries (Nori et al., 2011; Tsuji et al., 2010). On the other
hand, the use of iPSC-derived cells risks tumorigenesis
(Miura et al., 2009; Tsuji et al., 2010). The present study
demonstrates that even unsafe iPSC-NSs can confer thera-
peutic benefits against SCI, at least in the short term. How-
ever, long-term observation is required to assess the safety
of iPSC-NSs, because slow-growing tumors could causemo-
tor function to deteriorate over longer periods of time. In
the present study, we used retrovirally generated iPSCs (Na-
kagawa et al., 2008; Takahashi et al., 2007) and showed that
activation ofOCT4- and KLF4-Tgmight be related to tumor
formation. Thus, from a clinical-applications perspective,
NS/PCs derived from integration-free iPSCs (Okita et al.,
2008, 2011) should be chosen to avoid Tg-induced tumor-
igenesis. Recently, a pilot clinical study of integration-free
iPSC-based therapy for age-related macular degeneration
was approved following review by the Japanese govern-
ment (Garber, 2013; Kamao et al., 2014). As a step toward
clinical applications in the SCI field, we have already initi-
ated integration-free iPSC-NS transplantation in the NOD-
SCID mouse SCI model. At the same time, transplantation
into immune-deficient animals, accompanied by subse-
quent long-term observation, should be used to determine
the safety and effectiveness of these cells (Okano et al.,
2013).370 Stem Cell Reports j Vol. 4 j 360–373 j March 10, 2015 j ª2015 The AuthEXPERIMENTAL PROCEDURES
Additional details regarding several of the protocols used in this
work are provided in Supplemental Experimental Procedures.Cell Culture, Neural Differentiation, and Lentiviral
Transduction
Cell culture, neural differentiation of human iPSCs (253G1),
and lentiviral transduction of neurospheres were performed as
described previously (Nori et al., 2011; Okada et al., 2008). Briefly,
253G1-derived primary neurospheres were dissociated and in-
fected with lentivirus expressing Venus or ffLuc under the control
of the EF promoter. Primary neurospheres were passaged into sec-
ondary and tertiary neurospheres. The ffLuc vector enabled detec-
tion of grafted cells as strong bioluminescent ffLuc signals in live
SCI mice, and as fluorescent Venus signals in fixed spinal cord
sections.Animal Model and Cell Transplantation
Adult female NOD-SCID mice (20–22 g) were anesthetized via
intraperitoneal (i.p.) injection of ketamine (100 mg/kg) and xyla-
zine (10 mg/kg). After laminectomy, contusive SCI was induced
at the Th10 level using an IH impactor (60 kdyn; Precision Systems
and Instrumentation) as described previously (Scheff et al., 2003).
Nine days after SCI, 253G1-NSs (5 3 105 cells) were transplanted
into the lesion epicenter of eachmouse (n = 37) using a glassmicro-
pipette and stereotaxic injector (KDS310; Muromachi Kikai). The
253G1-NSs were transplanted at approximately the same time as
the PBS injection and 201B7-NS transplantation described in our
previous report (Nori et al., 2011).Bioluminescence Imaging
A Xenogen-IVIS spectrum-cooled, charge-coupled device optical
macroscopic imaging system (Summit Pharmaceuticals Interna-
tional) was used for bioluminescence imaging to confirm the sur-
vival of the grafted cells as previously described (Itakura et al.,
2014; Okada et al., 2005; Takahashi et al., 2011). Monitoring was
performed for 103 days post-transplantation.
Motor Function and Histological Analyses
Motor function was evaluated using the BMS, Rotarod apparatus
(Muromachi Kikai), and DigiGait system (Mouse Specifics). For
histological analyses, the animals were anesthetized and trans-
cardially perfused with 4% paraformaldehyde (pH 7.4). Spinal
cords were removed and sectioned in the sagittal/axial plane
on a cryostat. All motor function and histological analyses
were conducted by observers blinded to the treatment condi-
tions. All animal experiments (approval number 09169) were
performed under the control of the Keio University Institutional
Animal Care and Use Committee in accordance with the Institu-
tional Guidelines on Animal Experimentation at Keio University,
the Japanese Government Law Concerning the Protection and
Control of Animals, and the Japanese Government Notification
of Feeding and Safekeeping of Animals, and approved by the
ethics committee of Keio University (IRB approval number
09091-8).ors
RT-PCR
RNA isolation and RT-PCR were performed as previously described
(Nori et al., 2011; Okada et al., 2008).Transcriptome Analysis
Total RNA from each sample was purified as previously described
(Okada et al., 2008). mRNA libraries were prepared according to
the TruSeq RNA sample prep kit protocol and sequenced using a
Genome Analyzer IIx (Illumina). Mouse and human mRNA se-
quences were separated using Xenome software (Conway et al.,
2012), and separated mRNA-seq data were mapped to the corre-
sponding genomic DNA sequences (human [hg19] and mouse
[mm9]) using TopHat software (Trapnell et al., 2009). The map-
ped sequences were normalized by trimmed mean of M values
(TMM) and analyzed using Avadis NGS software (Agilent Tech-
nologies). All software used default parameters. For principal
component analysis (PCA) and clustering analysis, the normal-
ized data were narrowed down to 13,693 genes using a cutoff
value for expression levels (reads per kilobase of exon per
million mapped reads [RPKM] > 100). A Venn diagram was con-
structed to visualize the 1,715 genes that were upregulated in
the 253G1-NS/TP-103d group and the 1,358 genes that were up-
regulated in the 201B7-NS/TP-103d group (RPKM > 100, fold
change > 5.0 versus each NS group). GO analysis was performed
using gene lists from the overlapping area, as well as from each
separate area, in the Venn diagram. For GO analysis, p values
were calculated using Fisher’s exact test. Subsequently corrected
p values were applied for multiple testing corrections using the
Benjamini-Yekutieli method with a cutoff at p = 0.05. Pathway
analysis was performed via IPA (Ingenuity Systems) using
genes that were up- or downregulated in the 253G1-NS/TP-
103d group versus the 201B7-NS/TP-103d group, as well as in
253G1-NS versus 201B7-NS (RPKM > 100, fold-change > 3.0).
The genes were overlaid on the Ingenuity Knowledge Database
and networks were algorithmically generated based on their
connectivity. The p values were determined using Fisher’s exact
test and p = 0.05 was interpreted as indicating statistical
significance.Statistical Analyses
An unpaired, two-tailed Student’s t test was used to assess the
253G1-NS differentiation efficacy. One-way ANOVA followed
by the Tukey-Kramer test for multiple comparisons was used
for the Ki-67, Rotarod, and DigiGait analyses. Repeated-mea-
sures, two-way ANOVA followed by the Tukey-Kramer test was
used for the BMS analysis. The Kruskal-Wallis non-parametric
test and Scheffe’s test were used to analyze tumor diameter
and the percentage of HNu+ grafted cells that were Nestin+, Ki-
67+, or OCT4+. Statistical significance was determined as *p <
0.05, **p < 0.01.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and three tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
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